Literature DB >> 35530279

E2F1-mediated GINS2 transcriptional activation promotes tumor progression through PI3K/AKT/mTOR pathway in hepatocellular carcinoma.

Yao Zhang1, Xiaopei Hao1, Guoyong Han1, Yiwei Lu1, Zhiqiang Chen1, Long Zhang1, Jindao Wu1,2, Xuehao Wang1.   

Abstract

Hepatocellular carcinoma (HCC) has high morbidity and mortality rates. It is therefore imperative to study the underlying mechanism of HCC to identify potential prognostic biomarkers and therapeutic targets. Recently, GINS2 has been identified to be a cancer-promoting gene in different cancer types. Nevertheless, the exact mechanism of GINS2 in HCC remains to be elucidated. To systematically explore the significance of GINS2, we first assessed the relative expression of GINS2 in pan-cancers based on data obtained from the HCCDB, TIMER, and TCGA databases. Then, we explored the clinical significance of GINS2 in HCC through Kaplan-Meier method as well as univariate and multivariate cox regression analysis. Additionally, functional enrichment analysis of GINS2 was done through GO, KEGG, PPI network, and immune cell infiltration analyses. Functional experiments were also conducted to investigate the biological significance of GINS2 in HCC cell lines. Our research revealed that GINS2 is involved in HCC progression and highlighted its potential value as a crucial diagnostic and therapeutic target for HCC. AJCR
Copyright © 2022.

Entities:  

Keywords:  E2F1; GINS2; Hepatocellular carcinoma; PI3K/AKT/mTOR

Year:  2022        PMID: 35530279      PMCID: PMC9077065     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  38 in total

1.  GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks.

Authors:  Agnieszka Gambus; Richard C Jones; Alberto Sanchez-Diaz; Masato Kanemaki; Frederick van Deursen; Ricky D Edmondson; Karim Labib
Journal:  Nat Cell Biol       Date:  2006-03-12       Impact factor: 28.824

Review 2.  Visualizing transcription: key to understanding gene expression dynamics.

Authors:  Ineke Brouwer; Tineke L Lenstra
Journal:  Curr Opin Chem Biol       Date:  2019-07-05       Impact factor: 8.822

Review 3.  Surgery and Hepatocellular Carcinoma.

Authors:  Nobuhisa Akamatsu; Umberto Cillo; Alessandro Cucchetti; Matteo Donadon; Antonio Daniele Pinna; Guido Torzilli; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 5.  Immune checkpoint therapy in liver cancer.

Authors:  Feng Xu; Tianqiang Jin; Yuwen Zhu; Chaoliu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-05-29

6.  Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma.

Authors:  Deyu Zhang; Jiahong Liu; Tian Xie; Qiwei Jiang; Lihua Ding; Jianhua Zhu; Qinong Ye
Journal:  Int J Biol Sci       Date:  2020-08-27       Impact factor: 6.580

7.  Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway.

Authors:  Haixia Li; Jingyi Han; Jin Jiang; Jiang Wang; Jinghui Liang; Yongmeng Li; Zitong Feng; Renchang Zhao; Zhenguo Sun; Bin Lv; Hui Tian
Journal:  Cell Death Dis       Date:  2020-08-13       Impact factor: 8.469

8.  TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues.

Authors:  Áron Bartha; Balázs Győrffy
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

View more
  1 in total

1.  Targeting the Unwindosome by Mebendazole Is a Vulnerability of Chemoresistant Hepatoblastoma.

Authors:  Qian Li; Salih Demir; Álvaro Del Río-Álvarez; Rebecca Maxwell; Alexandra Wagner; Juan Carrillo-Reixach; Carolina Armengol; Christian Vokuhl; Beate Häberle; Dietrich von Schweinitz; Irene Schmid; Stefano Cairo; Roland Kappler
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.